RAMM Pharma Corp.
RAMM
CNSX
| 07/31/2024 | 04/30/2024 | 01/31/2024 | 10/31/2023 | 07/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 3.29M | 3.40M | 3.48M | 3.76M | 3.81M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.29M | 3.40M | 3.48M | 3.76M | 3.81M |
| Cost of Revenue | 2.92M | 3.22M | 3.28M | 3.47M | 2.93M |
| Gross Profit | 369.60K | 181.40K | 202.20K | 288.70K | 881.10K |
| SG&A Expenses | 5.41M | 5.45M | 5.25M | 5.54M | 6.48M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -11.60K | -5.70K | -1.60K | 300.00 | 0.00 |
| Total Operating Expenses | 8.31M | 8.66M | 8.53M | 9.01M | 9.41M |
| Operating Income | -5.03M | -5.26M | -5.05M | -5.25M | -5.60M |
| Income Before Tax | -6.53M | -6.58M | -6.17M | -5.70M | -15.23M |
| Income Tax Expenses | 7.10K | 7.10K | 7.10K | 7.10K | 6.30K |
| Earnings from Continuing Operations | -6.54 | -6.59 | -6.18 | -5.71 | -15.24 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6.54M | -6.59M | -6.18M | -5.71M | -15.24M |
| EBIT | -5.03M | -5.26M | -5.05M | -5.25M | -5.60M |
| EBITDA | -4.36M | -4.51M | -4.16M | -4.30M | -4.58M |
| EPS Basic | -0.05 | -0.06 | -0.05 | -0.05 | -0.12 |
| Normalized Basic EPS | -0.03 | -0.03 | -0.03 | -0.03 | -0.03 |
| EPS Diluted | -0.05 | -0.06 | -0.05 | -0.05 | -0.12 |
| Normalized Diluted EPS | -0.03 | -0.03 | -0.03 | -0.03 | -0.03 |
| Average Basic Shares Outstanding | 477.53M | 478.82M | 481.23M | 484.15M | 487.18M |
| Average Diluted Shares Outstanding | 477.53M | 478.82M | 481.23M | 484.15M | 487.18M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
